Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
about
Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative NeoplasmsMolecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia CellsOnce-daily dasatinib for treatment of patients with chronic myeloid leukemia.Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants.Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.Chronic myeloid leukemia: mechanisms of blastic transformationPrincipal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.Patients with chronic myeloid leukemia treated with imatinib who showed the appearance of clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells.Management of imatinib-resistant patients with chronic myeloid leukemia.Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.Treatment selection after imatinib resistance in chronic myeloid leukemia.Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms.Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.Genetic mechanisms of chronic myeloid leukemia blastic transformation.Treatment options for chronic myeloid leukemia.Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring.The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report.Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case reportConsiderations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.Philadelphia chromosome-negative acute myeloid leukemia with 11q23/MLL translocation in a patient with chronic myelogenous leukemiaImatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.Novel chromosomal aberration in Philadelphia negative cells of a patient with chronic myelogenous leukemia treated with dasatinib.Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.Genotoxicity associated with the use of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update.Sequential development of chronic myelogenous leukemia and primary myelofibrosis in a patient with history of large B-cell lymphoma treated with radiotherapy and chemotherapy: two myeloid neoplasms with distinct genotypic profiles suggestive of biclIncidence of transient single metaphase chromosomal abnormalities identified by routine metaphase cytogenetics in bone marrow specimens.Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant.
P2860
Q26799790-8002D009-85C5-4BF7-8AD6-3F5E557EBF64Q27853066-12D951B5-E97D-4559-9DFB-9CDD1DB5258EQ28550487-664E5903-36F0-479C-B627-0E660736FEBEQ33383954-A9B8AA43-7EFE-4107-AA9F-9BADA5F78553Q33633514-2C2A818B-7D7F-4730-A737-2B1C09A7592EQ33750753-70325EEE-715B-4EBD-9BF6-364F49A39AE5Q33766467-7CB81BB6-068D-4677-84DE-458DD6BB67CDQ33968037-4C59E34E-D13D-4AE4-BA5A-22364F37E6ACQ34443523-4A5FF18A-622A-46C0-B28C-5CF3FDAC6C0CQ35404394-7E863704-D8AD-4CAF-9011-0F4C0770A354Q35668398-AB75F574-17AB-4FE3-AC5A-BDFFA58FCAB1Q36776423-4978A5AC-FF30-4C95-9FDD-EF9186C0FFB2Q37163550-63EA42FF-E67B-4ACE-8750-371361736082Q37271941-8E3C8B5D-E4CC-401B-92A0-5C98BC478BB9Q37431597-26689311-7813-45A4-A826-EC5D724DB439Q37647076-40841A16-EA36-4C90-8375-D37223903189Q37651599-C016E08F-094C-49DA-A582-F40B83D99CBEQ37810110-4D041368-4B08-4584-AF5D-CF6D476F72DBQ37896015-009AC21E-B1B1-48F2-8787-88B1C79EC33AQ37983490-CA0A098E-A651-4241-BE0D-8649D4C4AAB2Q37994805-98DE5990-70D9-4357-97F1-2F8E2EBAEA30Q38095956-F67D381E-89B7-4546-AEF5-BAC8B13A0CAFQ38148233-CD017B7F-69AF-446F-B1DD-4D631D3FD3F4Q38598820-8D0342C7-09C9-409F-96BF-3A20176DC398Q38685696-55A88BE6-B58A-473F-AFDC-3F2328B00774Q41783949-24FA3E3A-3D9D-4F1F-BCA1-A35C5FC69B8FQ42117946-06D202FF-D962-4E64-B16E-B5F735D4D75AQ42126174-E743AC4F-4B78-4B5B-AD96-8DB4CFBB9117Q42532016-4A1CFA51-945A-4D89-BC28-0B24474CAB4EQ43078241-EB90FE84-1A29-4C8E-9F37-05548FE2C471Q43266877-7A687488-9A1F-45B5-A5C4-6ACC820BAAC6Q43291755-1E3937DE-38C1-47E4-816A-6AC0538C353BQ45895862-5869535C-BB17-4546-B73D-9A62DBCFBF98Q46606517-CF179C40-0A0E-483F-8A90-9C3B453990E4Q48186139-B247E50A-0712-4648-983E-B03D11356D37Q48333828-49718030-ED8B-4727-BD98-8E63F8D15740Q49993294-BB3EC720-AC0F-4BAB-B79B-429799F47749Q50227193-560B2474-331A-47CB-B770-68F81CEE1ACBQ53177290-C4BDEA75-04E0-41BD-AB9E-D955F0DD43E1Q53469467-73096B08-ADDF-42F7-BEC6-ABC79EBC3779
P2860
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Chromosomal abnormalities in P ...... oid leukemia in chronic phase.
@en
Chromosomal abnormalities in P ...... oid leukemia in chronic phase.
@nl
type
label
Chromosomal abnormalities in P ...... oid leukemia in chronic phase.
@en
Chromosomal abnormalities in P ...... oid leukemia in chronic phase.
@nl
prefLabel
Chromosomal abnormalities in P ...... oid leukemia in chronic phase.
@en
Chromosomal abnormalities in P ...... oid leukemia in chronic phase.
@nl
P50
P921
P1433
P1476
Chromosomal abnormalities in P ...... oid leukemia in chronic phase.
@en
P2093
Jianqin Shan
Lynne V Abruzzo
P304
P356
10.1182/BLOOD-2007-01-070045
P407
P50
P577
2007-07-11T00:00:00Z